Lavigne-Lissalde Géraldine, Rothschild Chantal, Pouplard Claire, Lapalud Priscilla, Gruel Yves, Schved Jean-François, Granier Claude
CNRS FRE 3009, Cap Delta/Parc Euromédecine, Montpellier, France.
Clin Rev Allergy Immunol. 2009 Oct;37(2):67-79. doi: 10.1007/s12016-009-8119-0.
The development of anti-factor VIII (FVIII) antibodies (Abs), also called inhibitors, is currently one of the most serious complications arising during the treatment of hemophilia A patients. Improved prevention and eradication of these Abs remain a challenge both for clinicians and scientists. Numerous studies in the literature have reported on their epitope specificity, on their mechanism of FVIII inactivation, as well as on the methods used for their detection. In this review, we summarize the current knowledge on the nature (isotypes, kinetic properties), epitope properties, and mechanisms of action of anti-FVIII Abs. Furthermore, we present methods for detection and epitope characterization of anti-FVIII Abs with emphasis on the Luminex technique susceptible to facilitate the monitoring of changes in the epitope specificity of these Abs.
抗凝血因子VIII(FVIII)抗体(Abs),也称为抑制剂,其产生目前是A型血友病患者治疗过程中出现的最严重并发症之一。改进这些抗体的预防和根除对临床医生和科学家而言仍是一项挑战。文献中的大量研究报道了它们的表位特异性、FVIII失活机制以及检测方法。在本综述中,我们总结了关于抗FVIII抗体的性质(同种型、动力学特性)、表位特性和作用机制的现有知识。此外,我们介绍了抗FVIII抗体的检测和表位表征方法,重点是Luminex技术,该技术有助于监测这些抗体表位特异性的变化。